Optimized Replicating Renilla Luciferase Reporter HIV-1 Utilizing Novel Internal Ribosome Entry Site Elements for Native Nef Expression and Function

AIDS Research and Human Retroviruses

Volumn 31, Issue 12, 2015, Pages 1278-1296

  Alberti, Michael O ^a   Jones, Jennifer J ^a   Miglietta, Riccardo ^a   Ding, Haitao ^a   Bakshi, Rakesh K ^a   Edmonds, Tara G ^a   Kappes, John C ^a,b,c,d   Ochsenbauer, Christina ^a,c,d  

^a and Clinical Center   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NEF PROTEIN; RENILLA LUCIFERIN 2 MONOOXYGENASE; HLA ANTIGEN CLASS 1; INTERNAL RIBOSOME ENTRY SITE; NEF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CRICKET PARALYSIS VIRUS; DOWN REGULATION; ENCEPHALOMYOCARDITIS VIRUS; ENVELOPE GENE; FLOW CYTOMETRY; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INTERNAL RIBOSOME ENTRY SITE; ISRAELI ACUTE PARALYSIS VIRUS; MYRISTYLATION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPORTER GENE; START CODON; STOP CODON; T LYMPHOCYTE; VIRUS GENOME; VIRUS INFECTIVITY; VIRUS LOAD; VIRUS PARTICLE; VIRUS REPLICATION; BIOSYNTHESIS; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; PHYSIOLOGY; PROTEIN SYNTHESIS; VIROLOGY;

CD4-POSITIVE T-LYMPHOCYTES; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENES, REPORTER; HISTOCOMPATIBILITY ANTIGENS CLASS I; HIV-1; HUMANS; INTERNAL RIBOSOME ENTRY SITES; LUCIFERASES, RENILLA; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PROTEIN BIOSYNTHESIS; VIRUS REPLICATION;

EID: 84948402639     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2015.0074     Document Type: Article

References (85)

1. Polonis VR, Brown BK, Rosa Borges A, et al.: Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology 2008;375(2):315-320.
2. Polonis VR, Schuitemaker H, Bunnik EM, et al.: Impact of host cell variation on the neutralization of HIV-1 in vitro. Curr Opin HIV AIDS 2009;4(5):400-407.
3. Ochsenbauer C and Kappes JC: New virologic reagents for neutralizing antibody assays. Curr Opin HIV AIDS 2009; 4(5):418-425.
4. Ochsenbauer C, Edmonds TG, Ding H, et al.: Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J Virol 2012;86(5):2715-2728.
5. Parrish NF, Wilen CB, Banks LB, et al.: Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin alpha4beta7. PLoS Pathog 2012;8(5): e1002686.
6. Salazar-Gonzalez JF, Salazar MG, Keele BF, et al.: Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 2009;206(6):1273-1289.
7. Ochiel DO, Ochsenbauer C, Kappes JC, et al.: Uterine epithelial cell regulation of DC-SIGN expression inhibits transmitted/founder HIV-1 trans infection by immature dendritic cells. PLoS One 2010;5(12):e14306.
8. Edmonds TG, Ding H, Yuan X, et al.: Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology 2010;408(1):1-13.
9. McLinden RJ, Labranche CC, Chenine AL, et al.: Detection of HIV-1 neutralizing antibodies in a human CD4(+)/CXCR4(+)/CCR5(+) T-lymphoblastoid cell assay system. PLoS One 2013;8(11):e77756.
10. Sarzotti-Kelsoe M, Daniell X, Todd CA, et al.: Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells. J Immunol Methods 2014;409:147-160.
11. Montefiori DC, Karnasuta C, Huang Y, et al.: Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis 2012;206(3):431-441.
12. Naarding MA, Fernandez N, Kappes JC, et al.: Development of a luciferase based viral inhibition assay to evaluate vaccine induced CD8 T-cell responses. J Immunol Methods 2014;409:161-173.
13. Smalls-Mantey A, Doria-Rose N, Klein R, et al.: Antibodydependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding. J Virol 2012;86(16):8672-8680.
14. Ferrari G, Pollara J, Kozink D, et al.: An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J Virol 2011;85(14): 7029-7036.
15. Pollara J, Hart L, Brewer F, et al.: High-throughput quantitative analysis of HIV-1 and SIV-specific ADCCmediating antibody responses. Cytometry A 2011;79(8): 603-612.
16. Seay K, Qi X, Zheng JH, et al.: Mice transgenic for CD4-specific human CD4, CCR5 and cyclin T1 expression: A new model for investigating HIV-1 transmission and treatment efficacy. PLoS One 2013;8(5):e63537.
17. deCamp A, Hraber P, Bailer RT, et al.: Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2014; 88(5):2489-2507.
18. Chenine AL, Wieczorek L, Sanders-Buell E, et al.: Impact of HIV-1 backbone on neutralization sensitivity: Neutralization profiles of heterologous envelope glycoproteins expressed in native subtype C and CRF01-AE backbone. PLoS One 2013;8(11):e76104.
19. Slichter CK, Friedrich DP, Smith RJ, et al.: Measuring inhibition of HIV replication by ex vivo CD8(+) T cells. J Immunol Methods 2014;404:71-80.
20. Planque SA, Mitsuda Y, Chitsazzadeh V, et al.: Deficient synthesis of class-switched, HIV-neutralizing antibodies to the CD4 binding site and correction by electrophilic gp120 immunogen. AIDS 2014;28(15):2201-2211.
21. Fenton-May AE, Dibben O, Emmerich T, et al.: Relative resistance of HIV-1 founder viruses to control by interferon-alpha. Retrovirology 2013;10:146.
22. Liu P, Yates NL, Shen X, et al.: Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. J Virol 2013;87(14):7828-7836.
23. Pace CS, Song R, Ochsenbauer C, et al.: Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1. Proc Natl Acad Sci USA 2013;110(33):13540-13545.
24. Miglietta R, Pastori C, Venuti A, et al.: Synergy in monoclonal antibody neutralization of HIV-1 pseudoviruses and infectious molecular clones. J Transl Med 2014;12(1):346.
25. Freel SA, Lamoreaux L, Chattopadhyay PK, et al.: Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. J Virol 2010;84(10):4998-5006.
26. Brown BK, Wieczorek L, Kijak G, et al.: The role of natural killer (NK) cells and NK cell receptor polymorphisms in the assessment of HIV-1 neutralization. PLoS One 2012; 7(4):e29454.
27. Levy DN, Aldrovandi GM, Kutsch O, and Shaw GM: Dynamics of HIV-1 recombination in its natural target cells. Proc Natl Acad Sci USA 2004;101(12):4204-4209.
28. Gelderblom HC, Vatakis DN, Burke SA, et al.: Viral complementation allows HIV-1 replication without integration. Retrovirology 2008;5:60.
29. Brown A, Gartner S, Kawano T, et al.: HLA-A2 downregulation on primary human macrophages infected with an M-tropic EGFP-tagged HIV-1 reporter virus. J Leukoc Biol 2005;78(3):675-685.
30. Mahlknecht U, Deng C, Lu MC, et al.: Resistance to apoptosis in HIV-infected CD4+ T lymphocytes is mediated by macrophages: Role for Nef and immune activation in viral persistence. J Immunol 2000;165(11):6437-6446.
31. Cohen GB, Gandhi RT, Davis DM, et al.: The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 1999;10(6):661-671.
32. de Felipe P: Skipping the co-expression problem: the new 2A "CHYSEL" technology. Genet Vaccines Ther 2004; 2(1):13.
33. Donnelly ML, Luke G, Mehrotra A, et al.: Analysis of the aphthovirus 2A/2B polyprotein 'cleavage' mechanism indicates not a proteolytic reaction, but a novel translational effect: A putative ribosomal 'skip.' J Gen Virol 2001;82(Pt 5): 1013-1025.
34. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al.: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361(23):2209-2220.
35. Pitisuttithum P, Gilbert P, Gurwith M, et al.: Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006;194(12):1661-1671.
36. Eisenhaber F, Eisenhaber B, Kubina W, et al.: Prediction of lipid posttranslational modifications and localization signals from protein sequences: Big-Pi, NMT and PTS1. Nucleic Acids Res 2003;31(13):3631-3634.
37. Maurer-Stroh S, Eisenhaber B, and Eisenhaber F: N-terminal N-myristoylation of proteins: Refinement of the sequence motif and its taxon-specific differences. J Mol Biol 2002; 317(4):523-540.
38. Welker R, Harris M, Cardel B, and Krausslich HG: Virion incorporation of human immunodeficiency virus type 1 Nef is mediated by a bipartite membrane-targeting signal: Analysis of its role in enhancement of viral infectivity. J Virol 1998;72(11):8833-8840.
39. Wei X, Decker JM, Liu H, et al.: Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002;46(6):1896-1905.
40. Folks T, Benn S, Rabson A, et al.: Characterization of a continuous T-cell line susceptible to the cytopathic effects of the acquired immunodeficiency syndrome (AIDS)-associated retrovirus. Proc Natl Acad Sci USA 1985;82(13): 4539-4543.
41. Duverger A, Wolschendorf F, Zhang M, et al.: An AP-1 binding site in the enhancer/core element of the HIV-1 promoter controls the ability of HIV-1 to establish latent infection. J Virol 2013;87(4):2264-2277.
42. Shishido T, Wolschendorf F, Duverger A, et al.: Selected drugs with reported secondary cell-differentiating capacity prime latent HIV-1 infection for reactivation. J Virol 2012; 86(17):9055-9069.
43. Hertz MI and Thompson SR: In vivo functional analysis of the Dicistroviridae intergenic region internal ribosome entry sites. Nucleic Acids Res 2011;39(16): 7276-7288.
44. Jang CJ, Lo MC, and Jan E: Conserved element of the dicistrovirus IGR IRES that mimics an E-site tRNA/ribosome interaction mediates multiple functions. J Mol Biol 2009;387(1):42-58.
45. Landry DM, Hertz MI, and Thompson SR: RPS25 is essential for translation initiation by the Dicistroviridae and hepatitis C viral IRESs. Genes Dev 2009;23(23):2753-2764.
46. Hertz MI, Landry DM, Willis AE, et al.: Ribosomal protein S25 dependency reveals a common mechanism for diverse internal ribosome entry sites and ribosome shunting. Mol Cell Biol 2013;33(5):1016-1026.
47. Bochkov YA and Palmenberg AC: Translational efficiency of EMCV IRES in bicistronic vectors is dependent upon IRES sequence and gene location. Biotechniques 2006;41(3): 283-284, 286, 288 passim.
48. Duke GM, Hoffman MA, and Palmenberg AC: Sequence and structural elements that contribute to efficient encephalomyocarditis virus RNA translation. J Virol 1992;66(3): 1602-1609.
49. Chappell SA, Edelman GM, and Mauro VP: A 9-nt segment of a cellular mRNA can function as an internal ribosome entry site (IRES) and when present in linked multiple copies greatly enhances IRES activity. Proc Natl Acad Sci USA 2000;97(4):1536-1541.
50. Bentham M, Mazaleyrat S, and Harris M: Role of myristoylation and N-terminal basic residues in membrane association of the human immunodeficiency virus type 1 Nef protein. J Gen Virol 2006;87(Pt 3):563-571.
51. Shugars DC, Smith MS, Glueck DH, et al.: Analysis of human immunodeficiency virus type 1 nef gene sequences present in vivo. J Virol 1993;67(8):4639-4650.
52. Chesebro B, Wehrly K, Nishio J, and Perryman S: Macrophagetropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: Definition of critical amino acids involved in cell tropism. J Virol 1992;66(11):6547-6554.
53. Muster T, Steindl F, Purtscher M, et al.: A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993;67(11):6642-6647.
54. Zwick MB, Labrijn AF, Wang M, et al.: Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001;75(22):10892-10905.
55. Burton DR, Pyati J, Koduri R, et al.: Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994;266(5187):1024-1027.
56. Bonsignori M, Montefiori DC, Wu X, et al.: Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: Implications for vaccine design. J Virol 2012;86(8):4688-4692.
57. Bonsignori M, Hwang KK, Chen X, et al.: Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol 2011;85(19):9998-10009.
58. Walker LM, Phogat SK, Chan-Hui PY, et al.: Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009;326(5950):285-289.
59. Pancera M, Shahzad-Ul-Hussan S, Doria-Rose NA, et al.: Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol 2013;20(7):804-813.
60. Trkola A, Purtscher M, Muster T, et al.: Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996;70(2):1100-1108.
61. Foster JL and Garcia JV: HIV-1 Nef: At the crossroads. Retrovirology 2008;5:84.
62. Kestler HW 3rd, Ringler DJ, Mori K, et al.: Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 1991;65(4):651-662.
63. Kirchhoff F, Greenough TC, Brettler DB, et al.: Brief report: Absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 1995;332(4):228-232.
64. Fackler OT, Moris A, Tibroni N, et al.: Functional characterization of HIV-1 Nef mutants in the context of viral infection. Virology 2006;351(2):322-339.
65. Borman AM, Le Mercier P, Girard M, and Kean KM: Comparison of picornaviral IRES-driven internal initiation of translation in cultured cells of different origins. Nucleic Acids Res 1997;25(5):925-932.
66. Jan E: Divergent IRES elements in invertebrates. Virus Res 2006;119(1):16-28.
67. Bonning BC and Miller WA: Dicistroviruses. Annu Rev Entomol 2010;55:129-150.
68. Piguet V and Trono D: In A Structure-Function Analysis of the Nef Protein of Primate Lentiviruses (Kuiken CL, Foley B, Hahn B, et al., eds.). Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, 1999.
69. Miller MD, Warmerdam MT, Ferrell SS, et al.: Intravirion generation of the C-terminal core domain of HIV-1 Nef by the HIV-1 protease is insufficient to enhance viral infectivity. Virology 1997;234(2):215-225.
70. Muller B, Daecke J, Fackler OT, et al.: Construction and characterization of a fluorescently labeled infectious human immunodeficiency virus type 1 derivative. J Virol 2004; 78(19):10803-10813.
71. Jamieson BD and Zack JA: In vivo pathogenesis of a human immunodeficiency virus type 1 reporter virus. J Virol 1998;72(8):6520-6526.
72. Herbein G, Van Lint C, Lovett JL, and Verdin E: Distinct mechanisms trigger apoptosis in human immunodeficiency virus type 1-infected and in uninfected bystander T lymphocytes. J Virol 1998;72(1):660-670.
73. Fouda GG, Mahlokozera T, Salazar-Gonzalez JF, et al.: Postnatally-transmitted HIV-1 envelope variants have similar neutralization-sensitivity and function to that of nontransmitted breast milk variants. Retrovirology 2013;10:3.
74. Collins KL, Chen BK, Kalams SA, et al.: HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 1998;391(6665):397-401.
75. Specht A, DeGottardi MQ, Schindler M, et al.: Selective downmodulation of HLA-A and-B by Nef alleles from different groups of primate lentiviruses. Virology 2008; 373(1):229-237.
76. Roff SR, Noon-Song EN, and Yamamoto JK: The significance of interferon-gamma in HIV-1 pathogenesis, therapy, and prophylaxis. Front Immunol 2014;4:498.
77. Schindler M, Rajan D, Specht A, et al.: Association of Nef with p21-activated kinase 2 is dispensable for efficient human immunodeficiency virus type 1 replication and cytopathicity in ex vivo-infected human lymphoid tissue. J Virol 2007;81(23):13005-13014.
78. Le Gall S, Erdtmann L, Benichou S, et al.: Nef interacts with the mu subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules. Immunity 1998;8(4):483-495.
79. Williams M, Roeth JF, Kasper MR, et al.: Direct binding of human immunodeficiency virus type 1 Nef to the major histocompatibility complex class I (MHC-I) cytoplasmic tail disrupts MHC-I trafficking. J Virol 2002;76(23):12173-12184.
80. Othman S and Yusof R: Regulation of MHC class I by viruses. In Histocompatibility (Abdel-Salam BKA-H, ed.). InTech Open Access Publisher, 2012, pp. 133-144.
81. Gavioli R, Gallerani E, Fortini C, et al.: HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity. J Immunol 2004;173(6):3838-3843.
82. Brodel AK, Sonnabend A, Roberts LO, et al.: IRES-mediated translation of membrane proteins and glycoproteins in eukaryotic cell-free systems. PLoS One 2013;8(12): e82234.
83. Fraser CS and Doudna JA: Structural and mechanistic insights into hepatitis C viral translation initiation. Nat Rev Microbiol 2007;5(1):29-38.
84. Owens GC, Chappell SA, Mauro VP, and Edelman GM: Identification of two short internal ribosome entry sites selected from libraries of random oligonucleotides. Proc Natl Acad Sci USA 2001;98(4):1471-1476.
85. Stoneley M, Paulin FE, Le Quesne JP, et al.: C-Myc 5' untranslated region contains an internal ribosome entry segment. Oncogene 1998;16(3):423-428.